Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CYAD-02 |
| Trade Name | |
| Synonyms | CYAD02|CYAD 02 |
| Drug Descriptions |
CYAD-02 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) encoding the Natural Killer Group 2D (NKG2D) receptor and an shRNA molecule targeting MICA and MICB, which may lead to increased anti-tumor activity (Blood 134 (2019): 3931). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C173710 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CYAD-02 | CYAD-02 | 0 | 1 |